News Release

Petricoin receives funding for cell signaling analysis of immune cells with targeted inhibitors

Grant and Award Announcement

George Mason University

Emanuel Petricoin, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received funding from Georgiamune, Inc., for a project in which Georgiamune, Inc., will provide cell pellets and CAPMM researchers will perform all aspects of the reverse phase protein array (RPPA) technology. These steps will include: lysate generation, plating, array printing, image analysis, and data extraction. CAPMM researchers will send data to Georgiamune, Inc., and researchers at both institutions will analyze the data. 

Petricoin received $30,558 from Georgiamune, Inc., for this research. Funding began in March 2022 and will end in late February 2023. 


About George Mason University

George Mason University is Virginia's largest public research university. Located near Washington, D.C., Mason enrolls 38,000 students from 130 countries and all 50 states. Mason has grown rapidly over the last half-century and is recognized for its innovation and entrepreneurship, remarkable diversity and commitment to accessibility. Learn more at

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.